|
1
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
|
JAMA
|
2003
|
97.28
|
|
2
|
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
|
Hypertension
|
2003
|
63.78
|
|
3
|
A controlled trial of renal denervation for resistant hypertension.
|
N Engl J Med
|
2014
|
14.22
|
|
4
|
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
|
N Engl J Med
|
2008
|
11.61
|
|
5
|
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.
|
Circulation
|
2010
|
9.07
|
|
6
|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
|
N Engl J Med
|
2013
|
8.74
|
|
7
|
Intensive blood-pressure control in hypertensive chronic kidney disease.
|
N Engl J Med
|
2010
|
8.48
|
|
8
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
N Engl J Med
|
2013
|
7.54
|
|
9
|
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
|
Lancet
|
2012
|
6.69
|
|
10
|
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
|
N Engl J Med
|
2014
|
5.93
|
|
11
|
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
|
JAMA
|
2003
|
5.67
|
|
12
|
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
|
JAMA
|
2010
|
5.06
|
|
13
|
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine.
|
J Am Coll Cardiol
|
2010
|
4.90
|
|
14
|
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
|
Circulation
|
2006
|
4.61
|
|
15
|
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.
|
Diabetes Care
|
2007
|
4.30
|
|
16
|
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.
|
Arch Intern Med
|
2003
|
4.08
|
|
17
|
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review.
|
Hypertension
|
2006
|
3.89
|
|
18
|
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
|
Arch Intern Med
|
2008
|
3.71
|
|
19
|
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension.
|
J Clin Hypertens (Greenwich)
|
2013
|
2.94
|
|
20
|
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.
|
J Hypertens
|
2014
|
2.82
|
|
21
|
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
|
Clin Chem
|
2011
|
2.82
|
|
22
|
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
|
Diabetes Care
|
2011
|
2.75
|
|
23
|
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).
|
Am J Kidney Dis
|
2003
|
2.68
|
|
24
|
Resistant hypertension: an overview of evaluation and treatment.
|
J Am Coll Cardiol
|
2008
|
2.63
|
|
25
|
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.
|
Am J Cardiol
|
2006
|
2.58
|
|
26
|
Cardiovascular events during differing hypertension therapies in patients with diabetes.
|
J Am Coll Cardiol
|
2010
|
2.43
|
|
27
|
The pathogenesis of diabetic nephropathy.
|
Nat Clin Pract Endocrinol Metab
|
2008
|
2.34
|
|
28
|
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.
|
J Hypertens
|
2014
|
2.28
|
|
29
|
Awareness of kidney disease and relationship to end-stage renal disease and mortality.
|
Am J Med
|
2012
|
2.24
|
|
30
|
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2010
|
2.18
|
|
31
|
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.
|
Catheter Cardiovasc Interv
|
2010
|
2.14
|
|
32
|
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).
|
Arch Intern Med
|
2007
|
2.14
|
|
33
|
Hypertension awareness, treatment, and control in chronic kidney disease.
|
Am J Med
|
2008
|
2.11
|
|
34
|
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.
|
Eur Heart J
|
2012
|
1.95
|
|
35
|
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2011
|
1.88
|
|
36
|
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
|
Arch Intern Med
|
2005
|
1.76
|
|
37
|
Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease.
|
Vasc Med
|
2002
|
1.73
|
|
38
|
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
|
J Natl Cancer Inst
|
2010
|
1.73
|
|
39
|
Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
|
Diabetes Care
|
2011
|
1.71
|
|
40
|
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
|
Hypertension
|
2011
|
1.69
|
|
41
|
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions.
|
Am J Hypertens
|
2009
|
1.66
|
|
42
|
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control.
|
Kidney Int
|
2013
|
1.65
|
|
43
|
Body weight changes with beta-blocker use: results from GEMINI.
|
Am J Med
|
2007
|
1.60
|
|
44
|
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.
|
JAMA
|
2013
|
1.54
|
|
45
|
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
|
Blood Press
|
2007
|
1.52
|
|
46
|
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES).
|
Am J Kidney Dis
|
2009
|
1.52
|
|
47
|
Combination therapy in hypertension.
|
J Am Soc Hypertens
|
2010
|
1.51
|
|
48
|
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
|
Kidney Int
|
2011
|
1.51
|
|
49
|
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
|
J Clin Hypertens (Greenwich)
|
2007
|
1.50
|
|
50
|
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies.
|
Circ Heart Fail
|
2010
|
1.50
|
|
51
|
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.
|
Anesth Analg
|
2010
|
1.50
|
|
52
|
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
|
Blood Press
|
2005
|
1.49
|
|
53
|
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.
|
Am J Geriatr Cardiol
|
2008
|
1.48
|
|
54
|
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute.
|
Hypertension
|
2008
|
1.46
|
|
55
|
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.
|
Am Heart J
|
2008
|
1.46
|
|
56
|
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.44
|
|
57
|
State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.
|
J Clin Hypertens (Greenwich)
|
2008
|
1.38
|
|
58
|
Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women.
|
J Womens Health (Larchmt)
|
2012
|
1.38
|
|
59
|
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
|
Diabetes Care
|
2005
|
1.36
|
|
60
|
Renal handling of albumin: a critical review of basic concepts and perspective.
|
Am J Kidney Dis
|
2002
|
1.35
|
|
61
|
Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
|
Clin Chem
|
2011
|
1.32
|
|
62
|
Combination therapy in hypertension.
|
J Am Soc Hypertens
|
2010
|
1.28
|
|
63
|
CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2008
|
1.26
|
|
64
|
Resistant hypertension--its identification and epidemiology.
|
Nat Rev Nephrol
|
2012
|
1.26
|
|
65
|
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
|
Am J Nephrol
|
2009
|
1.23
|
|
66
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
Am J Nephrol
|
2013
|
1.23
|
|
67
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
Am J Med
|
2012
|
1.22
|
|
68
|
An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease.
|
Am J Nephrol
|
2006
|
1.21
|
|
69
|
Antihypertensive therapy in the presence of proteinuria.
|
Am J Kidney Dis
|
2007
|
1.20
|
|
70
|
Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program.
|
Kidney Int
|
2005
|
1.18
|
|
71
|
Association of NEDD4L ubiquitin ligase with essential hypertension.
|
Hypertension
|
2005
|
1.17
|
|
72
|
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.
|
Am J Med
|
2013
|
1.17
|
|
73
|
Chronic kidney disease: a coronary heart disease equivalent?
|
Lancet
|
2012
|
1.16
|
|
74
|
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
|
Blood Press
|
2007
|
1.15
|
|
75
|
beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality.
|
Arch Intern Med
|
2004
|
1.14
|
|
76
|
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
|
Hypertension
|
2012
|
1.14
|
|
77
|
A comparative evaluation of various methods for microalbuminuria screening.
|
Am J Nephrol
|
2007
|
1.13
|
|
78
|
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
|
J Clin Hypertens (Greenwich)
|
2007
|
1.12
|
|
79
|
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
|
Am J Cardiol
|
2006
|
1.12
|
|
80
|
Combination therapy in hypertension.
|
J Clin Hypertens (Greenwich)
|
2010
|
1.09
|
|
81
|
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.
|
Am J Kidney Dis
|
2013
|
1.08
|
|
82
|
The kidney, hypertension, and remaining challenges.
|
Med Clin North Am
|
2009
|
1.08
|
|
83
|
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
|
Blood Press
|
2008
|
1.08
|
|
84
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
Nephrol Dial Transplant
|
2013
|
1.07
|
|
85
|
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease.
|
Nephrol Dial Transplant
|
2006
|
1.07
|
|
86
|
Renal function and target organ damage in hypertension.
|
Eur Heart J
|
2011
|
1.06
|
|
87
|
Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study.
|
J Am Soc Hypertens
|
2010
|
1.04
|
|
88
|
Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2009
|
1.04
|
|
89
|
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
Am J Nephrol
|
2014
|
1.04
|
|
90
|
Association of BP variability with mortality among African Americans with CKD.
|
Clin J Am Soc Nephrol
|
2013
|
1.03
|
|
91
|
Heart failure as a cause for hospitalization in chronic dialysis patients.
|
Am J Kidney Dis
|
2003
|
1.03
|
|
92
|
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
|
J Clin Hypertens (Greenwich)
|
2005
|
1.02
|
|
93
|
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
|
Eur Heart J
|
2012
|
1.02
|
|
94
|
Chronic kidney disease as a coronary artery disease risk equivalent.
|
Curr Cardiol Rep
|
2013
|
1.01
|
|
95
|
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease.
|
Metabolism
|
2009
|
1.00
|
|
96
|
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
|
J Clin Hypertens (Greenwich)
|
2008
|
0.99
|
|
97
|
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
|
Nat Rev Nephrol
|
2013
|
0.99
|
|
98
|
Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible?
|
J Clin Hypertens (Greenwich)
|
2009
|
0.99
|
|
99
|
Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension.
|
J Hypertens
|
2009
|
0.96
|
|
100
|
Treatment of hypertension in patients with renal disease.
|
Cardiovasc Drugs Ther
|
2002
|
0.96
|
|
101
|
Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome.
|
Postgrad Med
|
2002
|
0.96
|
|
102
|
Isolated diastolic hypotension and incident heart failure in older adults.
|
Hypertension
|
2011
|
0.96
|
|
103
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.95
|
|
104
|
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
|
Am J Hypertens
|
2004
|
0.95
|
|
105
|
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.
|
J Hypertens
|
2007
|
0.95
|
|
106
|
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
|
Am Heart J
|
2011
|
0.94
|
|
107
|
Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained.
|
Postgrad Med
|
2002
|
0.94
|
|
108
|
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
|
J Clin Hypertens (Greenwich)
|
2006
|
0.94
|
|
109
|
National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary.
|
Am J Kidney Dis
|
2010
|
0.94
|
|
110
|
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented.
|
Kidney Int
|
2009
|
0.94
|
|
111
|
Effects of thiazolidinediones beyond glycaemic control.
|
Curr Pharm Des
|
2009
|
0.93
|
|
112
|
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome.
|
Curr Diab Rep
|
2006
|
0.93
|
|
113
|
Renin-angiotensin blockade and kidney disease.
|
Lancet
|
2008
|
0.93
|
|
114
|
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
|
Hypertension
|
2004
|
0.93
|
|
115
|
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program.
|
Cardiorenal Med
|
2011
|
0.93
|
|
116
|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
|
Semin Nephrol
|
2004
|
0.93
|
|
117
|
Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
|
Diabetes Care
|
2007
|
0.91
|
|
118
|
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
|
J Clin Hypertens (Greenwich)
|
2006
|
0.91
|
|
119
|
Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting.
|
Am Heart J
|
2006
|
0.90
|
|
120
|
The past, present and future of renin-angiotensin aldosterone system inhibition.
|
Int J Cardiol
|
2012
|
0.90
|
|
121
|
Epidemiology of hypertensive kidney disease.
|
Nat Rev Nephrol
|
2010
|
0.89
|
|
122
|
The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance?
|
Am J Nephrol
|
2007
|
0.89
|
|
123
|
Effects of angiotensin II receptor blockers on diabetic nephropathy.
|
J Hypertens Suppl
|
2009
|
0.89
|
|
124
|
Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease.
|
Semin Nephrol
|
2010
|
0.89
|
|
125
|
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2011
|
0.88
|
|
126
|
Calcium antagonists: effects on cardio-renal risk in hypertensive patients.
|
Hypertension
|
2005
|
0.88
|
|
127
|
Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2010
|
0.88
|
|
128
|
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
|
Am J Nephrol
|
2009
|
0.88
|
|
129
|
Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
|
Prog Brain Res
|
2002
|
0.88
|
|
130
|
Obesity and insulin resistance as risk factors for chronic kidney disease.
|
J Cardiometab Syndr
|
2006
|
0.87
|
|
131
|
Rationale for establishing a mechanism to increase reimbursement to hypertension specialists.
|
J Clin Hypertens (Greenwich)
|
2013
|
0.87
|
|
132
|
Cardiometabolic syndrome and chronic kidney disease: what is the link?
|
J Cardiometab Syndr
|
2006
|
0.87
|
|
133
|
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
|
J Natl Med Assoc
|
2006
|
0.87
|
|
134
|
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.
|
J Clin Hypertens (Greenwich)
|
2004
|
0.86
|
|
135
|
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
|
Blood Press
|
2007
|
0.86
|
|
136
|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
|
Hypertension
|
2012
|
0.86
|
|
137
|
Interaction between Adiponectin and Aldosterone.
|
Cardiorenal Med
|
2011
|
0.85
|
|
138
|
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2009
|
0.85
|
|
139
|
Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial.
|
Blood Press Monit
|
2005
|
0.85
|
|
140
|
The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease.
|
Cardiorenal Med
|
2011
|
0.85
|
|
141
|
Should beta-blockers be used to control hypertension in people with chronic kidney disease?
|
Semin Nephrol
|
2007
|
0.85
|
|
142
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
Oncologist
|
2013
|
0.84
|
|
143
|
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
|
Prev Cardiol
|
2005
|
0.84
|
|
144
|
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
|
Am Heart J
|
2012
|
0.83
|
|
145
|
Novel therapies of diabetic nephropathy.
|
Curr Opin Nephrol Hypertens
|
2009
|
0.83
|
|
146
|
Review: Insulin and endothelin: an interplay contributing to hypertension development?
|
J Clin Endocrinol Metab
|
2006
|
0.83
|
|
147
|
Hypertensive nephropathy: prevention and treatment recommendations.
|
Expert Opin Pharmacother
|
2010
|
0.83
|
|
148
|
Microalbuminuria: what is it? Why is it important? What should be done about it? An update.
|
J Clin Hypertens (Greenwich)
|
2007
|
0.83
|
|
149
|
Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
|
Am J Nephrol
|
2010
|
0.83
|
|
150
|
Blood pressure control and nephroprotection in diabetes.
|
J Clin Pharmacol
|
2004
|
0.83
|
|
151
|
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
|
J Clin Hypertens (Greenwich)
|
2005
|
0.83
|
|
152
|
Mechanistic insights into diuretic-induced insulin resistance.
|
Hypertension
|
2008
|
0.82
|
|
153
|
Antihypertensive therapy and the risk of new-onset diabetes.
|
Diabetes Care
|
2006
|
0.82
|
|
154
|
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
|
Blood Press
|
2011
|
0.82
|
|
155
|
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial.
|
Am J Hypertens
|
2003
|
0.82
|
|
156
|
Level of kidney function determines cardiovascular fate after coronary bypass graft surgery.
|
Circulation
|
2006
|
0.81
|
|
157
|
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
|
Hypertension
|
2010
|
0.81
|
|
158
|
Hypertension control rates: time for translation of guidelines into clinical practice.
|
Am J Med
|
2004
|
0.81
|
|
159
|
Comparison of commonly used assays for the detection of microalbuminuria.
|
J Clin Hypertens (Greenwich)
|
2004
|
0.81
|
|
160
|
Importance of blood pressure control in left ventricular mass regression.
|
J Am Soc Hypertens
|
2010
|
0.81
|
|
161
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
Am J Nephrol
|
2015
|
0.81
|
|
162
|
Renal denervation for resistant hypertension.
|
N Engl J Med
|
2014
|
0.81
|
|
163
|
Pharmacological augmentation of endothelium-derived nitric oxide synthesis.
|
J Manag Care Pharm
|
2007
|
0.81
|
|
164
|
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
|
Am J Hypertens
|
2004
|
0.81
|
|
165
|
The role of calcium antagonists in chronic kidney disease.
|
Curr Opin Nephrol Hypertens
|
2004
|
0.81
|
|
166
|
Do fibrates truly preserve kidney function?
|
Nat Rev Endocrinol
|
2011
|
0.81
|
|
167
|
Microalbuminuria.
|
Clin Lab Med
|
2006
|
0.80
|
|
168
|
Prehypertension: is it relevant for nephrologists?
|
Kidney Int
|
2009
|
0.80
|
|
169
|
Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies.
|
Hypertension
|
2013
|
0.80
|
|
170
|
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.
|
J Hypertens
|
2016
|
0.80
|
|
171
|
Controlled-release carvedilol in the treatment of essential hypertension.
|
Am J Cardiol
|
2006
|
0.80
|
|
172
|
Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
|
Am Heart J
|
2004
|
0.80
|
|
173
|
Hypertension goals in advanced-stage kidney disease.
|
Clin J Am Soc Nephrol
|
2009
|
0.80
|
|
174
|
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.
|
J Clin Hypertens (Greenwich)
|
2006
|
0.79
|
|
175
|
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
|
J Clin Hypertens (Greenwich)
|
2002
|
0.79
|
|
176
|
Antihypertensive agents, insulin sensitivity, and new-onset diabetes.
|
Curr Diab Rep
|
2007
|
0.79
|
|
177
|
The cardiometabolic syndrome and calcium channel blocker combination drugs.
|
J Cardiometab Syndr
|
2007
|
0.79
|
|
178
|
Hypertension: the message of World Kidney Day 2009.
|
Nat Rev Nephrol
|
2009
|
0.79
|
|
179
|
Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
|
J Clin Hypertens (Greenwich)
|
2006
|
0.79
|
|
180
|
Management of hypertension in the elderly population.
|
J Gerontol A Biol Sci Med Sci
|
2012
|
0.79
|
|
181
|
Comparative efficacy of two different beta-blockers on 24-hour blood pressure control.
|
J Clin Hypertens (Greenwich)
|
2008
|
0.79
|
|
182
|
Renal hemodynamic changes in heart failure.
|
Heart Fail Clin
|
2008
|
0.79
|
|
183
|
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
|
Curr Opin Nephrol Hypertens
|
2009
|
0.79
|
|
184
|
Protein kinase C-beta inhibition: a promise not yet fulfilled.
|
Clin J Am Soc Nephrol
|
2007
|
0.79
|
|
185
|
Predictors of hypertension control in a diverse general cardiology practice.
|
J Clin Hypertens (Greenwich)
|
2010
|
0.79
|
|
186
|
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
|
J Clin Hypertens (Greenwich)
|
2007
|
0.79
|
|
187
|
Is proteinuria a plausible target of therapy?
|
Curr Hypertens Rep
|
2004
|
0.79
|
|
188
|
Pulse pressure and arterial stiffness: an emerging renal risk predictor?
|
J Hypertens
|
2007
|
0.79
|
|
189
|
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
|
Blood Press Monit
|
2014
|
0.79
|
|
190
|
Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk.
|
Curr Vasc Pharmacol
|
2010
|
0.79
|
|
191
|
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
|
J Hypertens
|
2004
|
0.79
|
|
192
|
Current and future potassium binders.
|
Nephrol News Issues
|
2016
|
0.79
|
|
193
|
Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents.
|
J Hypertens
|
2007
|
0.78
|
|
194
|
Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach.
|
J Cardiometab Syndr
|
2006
|
0.78
|
|
195
|
The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome.
|
Am J Med
|
2010
|
0.78
|
|
196
|
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.
|
J Cardiometab Syndr
|
2008
|
0.78
|
|
197
|
Glycemic control and cardiovascular disease in chronic kidney disease.
|
Curr Diab Rep
|
2009
|
0.78
|
|
198
|
Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?
|
Ann Intern Med
|
2009
|
0.78
|
|
199
|
The current state of RAAS blockade in the treatment of hypertension and proteinuria.
|
Curr Cardiol Rep
|
2009
|
0.78
|
|
200
|
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
|
N Engl J Med
|
2010
|
0.78
|
|
201
|
The promise of renal denervation.
|
Cleve Clin J Med
|
2012
|
0.78
|
|
202
|
Diabetes and chronic kidney disease: tragedy and challenge.
|
Blood Purif
|
2004
|
0.78
|
|
203
|
Role of ambulatory blood pressure monitoring in hypertension and diabetes.
|
Curr Hypertens Rep
|
2013
|
0.78
|
|
204
|
Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy.
|
Contrib Nephrol
|
2011
|
0.78
|
|
205
|
Assessing blood pressure control in dialysis patients: finally a step forward.
|
Hypertension
|
2009
|
0.78
|
|
206
|
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
|
Am J Nephrol
|
2005
|
0.78
|
|
207
|
Albuminuria and cardiovascular risk.
|
Heart Fail Clin
|
2006
|
0.78
|
|
208
|
Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on "intensive and standard blood pressure targets in patients with type 2 diabetes mellitus".
|
Arch Intern Med
|
2012
|
0.77
|
|
209
|
Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches.
|
J Clin Hypertens (Greenwich)
|
2014
|
0.77
|
|
210
|
Blood pressure targets for patients with diabetes or kidney disease.
|
Curr Hypertens Rep
|
2011
|
0.77
|
|
211
|
Beta-blockers in the treatment of hypertension: new data, new directions.
|
J Clin Hypertens (Greenwich)
|
2008
|
0.77
|
|
212
|
Recognition and management of masked hypertension: a review and novel approach.
|
J Am Soc Hypertens
|
2013
|
0.77
|
|
213
|
Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP).
|
Am J Kidney Dis
|
2011
|
0.77
|
|
214
|
Effects of naproxcinod on blood pressure in patients with osteoarthritis.
|
Am J Cardiol
|
2011
|
0.77
|
|
215
|
Case study: the link between hypertension and diabetes.
|
J Manag Care Pharm
|
2007
|
0.77
|
|
216
|
What have we learned from the current trials?
|
Med Clin North Am
|
2004
|
0.77
|
|
217
|
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented.
|
Clin J Am Soc Nephrol
|
2009
|
0.77
|
|
218
|
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.
|
Curr Hypertens Rep
|
2002
|
0.77
|
|
219
|
National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary.
|
Am J Kidney Dis
|
2011
|
0.77
|
|
220
|
Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes.
|
Curr Vasc Pharmacol
|
2012
|
0.77
|
|
221
|
Timing and efficacy of alternative methods of sympathetic blockade.
|
Curr Hypertens Rep
|
2012
|
0.76
|
|
222
|
The future of renal denervation in resistant hypertension.
|
Curr Hypertens Rep
|
2014
|
0.76
|
|
223
|
Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients.
|
J Hypertens
|
2014
|
0.76
|
|
224
|
Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study.
|
Curr Hypertens Rep
|
2010
|
0.76
|
|
225
|
Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report.
|
Am J Kidney Dis
|
2009
|
0.76
|
|
226
|
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
|
Blood Purif
|
2016
|
0.76
|
|
227
|
Are beta blockers passé for the treatment of hypertension?
|
J Clin Hypertens (Greenwich)
|
2006
|
0.76
|
|
228
|
Interventional cardiology: Indications for renal denervation: a balanced approach?
|
Nat Rev Cardiol
|
2013
|
0.76
|
|
229
|
Hypertension treatment guidelines: practical implications.
|
Semin Nephrol
|
2005
|
0.76
|
|
230
|
Is blockade of the renin-angiotensin system appropriate for all patients with diabetes?
|
J Am Soc Hypertens
|
2010
|
0.76
|
|
231
|
Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly.
|
Am J Nephrol
|
2013
|
0.76
|
|
232
|
Lower blood pressure goals in high-risk cardiovascular patients: are they defensible?
|
Cardiol Clin
|
2010
|
0.76
|
|
233
|
When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk.
|
Hypertension
|
2004
|
0.76
|
|
234
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
Curr Hypertens Rep
|
2003
|
0.76
|
|
235
|
Approaches for targeting blood pressure control in sleep disorders.
|
Curr Opin Nephrol Hypertens
|
2012
|
0.75
|
|
236
|
Lifestyle changes and unanswered questions about hypertension and cardiovascular risk.
|
Curr Hypertens Rep
|
2007
|
0.75
|
|
237
|
Should a lower blood pressure goal and albuminuria reduction be mandated to slow hypertensive nephropathy?
|
Curr Hypertens Rep
|
2008
|
0.75
|
|
238
|
Obesity, blood pressure, and cardiovascular outcomes - Authors' reply.
|
Lancet
|
2013
|
0.75
|
|
239
|
The future of blood pressure control in a population with a growing girth.
|
Curr Opin Nephrol Hypertens
|
2009
|
0.75
|
|
240
|
The author replies.
|
Kidney Int
|
2013
|
0.75
|
|
241
|
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus.
|
Hypertension
|
2013
|
0.75
|
|
242
|
More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors.
|
J Hypertens
|
2010
|
0.75
|
|
243
|
Beta-blocker therapy in hypertension: a need to pause and reflect.
|
J Am Coll Cardiol
|
2008
|
0.75
|
|
244
|
New agents for hyperkalemia.
|
N Engl J Med
|
2015
|
0.75
|
|
245
|
Albuminuria reduction and nephropathy progression.
|
Curr Hypertens Rep
|
2008
|
0.75
|
|
246
|
Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
247
|
Hypertension and diabetes: family physicians' pivotal role.
|
Am Fam Physician
|
2002
|
0.75
|
|
248
|
Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
|
Pharmacoeconomics
|
2002
|
0.75
|
|
249
|
Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP).
|
Diabetes Care
|
2010
|
0.75
|
|
250
|
Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?
|
Am J Kidney Dis
|
2003
|
0.75
|
|
251
|
Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease?
|
J Hypertens
|
2012
|
0.75
|
|
252
|
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated?
|
J Renin Angiotensin Aldosterone Syst
|
2014
|
0.75
|
|
253
|
Clinical implications of blockade of the renin-angiotensin system in management of hypertension.
|
Contrib Nephrol
|
2004
|
0.75
|
|
254
|
Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade.
|
Heart Fail Clin
|
2008
|
0.75
|
|
255
|
Evaluation and treatment of patients with systemic hypertension.
|
Circulation
|
2002
|
0.75
|
|
256
|
Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes?
|
Nat Clin Pract Endocrinol Metab
|
2007
|
0.75
|
|
257
|
Cardiology patient page. Kidney failure and cardiovascular disease.
|
Circulation
|
2003
|
0.75
|
|
258
|
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.
|
J Clin Hypertens (Greenwich)
|
2003
|
0.75
|
|
259
|
Update on blood pressure goals in diabetes mellitus.
|
Curr Cardiol Rep
|
2015
|
0.75
|
|
260
|
Does dietary salt increase the risk for progression of kidney disease?
|
Curr Hypertens Rep
|
2005
|
0.75
|
|
261
|
Retraction statement.
|
Am J Nephrol
|
2009
|
0.75
|
|
262
|
OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS: RESULTS FROM OPAL-HK.
|
J Hypertens
|
2016
|
0.75
|
|
263
|
Hypertension and its management in the elderly.
|
Semin Nephrol
|
2009
|
0.75
|
|
264
|
An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements.
|
J Clin Hypertens (Greenwich)
|
2006
|
0.75
|
|
265
|
Newer combination therapies in the management of hypertension: an update.
|
J Clin Hypertens (Greenwich)
|
2008
|
0.75
|
|
266
|
Fixed-dose combination and chronic kidney disease progression: which is the best?
|
Curr Opin Nephrol Hypertens
|
2010
|
0.75
|
|
267
|
Hypertensive goals in patients with coronary artery disease.
|
Curr Cardiol Rep
|
2012
|
0.75
|
|
268
|
Renal adaptation to the failing heart.
|
Postgrad Med
|
1994
|
0.75
|
|
269
|
The editor's roundtable: revisiting the role of beta blockers in hypertension.
|
Am J Cardiol
|
2007
|
0.75
|
|
270
|
The editor's roundtable: prehypertension.
|
Am J Cardiol
|
2009
|
0.75
|
|
271
|
Drug dosing in patients with renal insufficiency.
|
Postgrad Med
|
1993
|
0.75
|
|
272
|
Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
|
Curr Opin Nephrol Hypertens
|
2011
|
0.75
|
|
273
|
The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented.
|
Nephrology (Carlton)
|
2009
|
0.75
|
|
274
|
Management of hypertension in the cardiometabolic syndrome and diabetes.
|
Curr Diab Rep
|
2004
|
0.75
|
|
275
|
CLINICAL DECISIONS. Blood-Pressure Control.
|
N Engl J Med
|
2015
|
0.75
|
|
276
|
Renal adaptation to the failing heart.
|
Postgrad Med
|
1994
|
0.75
|
|
277
|
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.
|
Ann Intern Med
|
2008
|
0.75
|
|
278
|
ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
|
J Clin Hypertens (Greenwich)
|
2007
|
0.75
|
|
279
|
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
|
Pol Arch Med Wewn
|
2007
|
0.75
|
|
280
|
OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS: RESULTS FROM OPAL-HK.
|
J Hypertens
|
2016
|
0.75
|
|
281
|
Roundtable discussion: problems in the management of hypertension.
|
J Clin Hypertens (Greenwich)
|
2002
|
0.75
|
|
282
|
The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented.
|
Pediatr Nephrol
|
2009
|
0.75
|